Bone Biologics (BBLG) Action Cours

Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. The NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. The NELL-1/DBM Fusion Device offers a range of procedures, including Spine Implants, Non-Union Trauma Cases and Osteoporosis. The NELL-1 is a function specific recombinant human protein that has been proven in laboratory bench models to recapitulate normal human growth and development to provide control over bone and cartilage regeneration. The firm develops platform technology through significant laboratories and small and large animal research to generate applications across fields of use. The platform technology is its recombinant human protein, known as NELL-1, a skeletal specific growth factor which is a bone void filler.